Page 91 - 《中国药房》2024年2期

patterns of breast cancer incidence and mortality：a Chinese Society of Clinical Oncology. Chinese Society of
population-based cancer registry data analysis from 2000 Clinical Oncology（CSCO）guidelines for the diagnosis
to 2020[J]. Cancer Commun，2021，41（11）：1183-1194. and treatment of breast cancer 2023[M]. Beijing：People’s
[ 3 ] CAO M M，LI H，SUN D Q，et al. Cancer burden of major Medical Publishing House，2023：87.
cancers in China：a need for sustainable actions[J]. Cancer [14] SAURA C，OLIVEIRA M，FENG Y H，et al. Neratinib
Commun，2020，40（5）：205-210. plus capecitabine versus lapatinib plus capecitabine in
[ 4 ] SUN Y，LI W Q，LI A J，et al. Increased systemic immune- HER2-positive metastatic breast cancer previously treated
inflammation index independently predicts poor survival with ≥2 HER2-directed regimens：phase Ⅲ NALA trial
for hormone receptor-negative，HER2-positive breast can‐ [J]. J Clin Oncol，2020，38（27）：3138-3149.
cer patients[J]. Cancer Manag Res，2019，11：3153-3162. [15] WU Y，DONG Z，WANG J F，et al. Neratinib plus
[ 5 ] 李阁，谷瑞雪，刘旭，等. Her-2阳性乳腺癌靶向治疗药物 capecitabine versus lapatinib plus capecitabine as the
的研究进展[J]. 肿瘤学杂志，2020，26（1）：1-6. third-line therapy for HER2-positive metastatic breast can‐
LI G，GU R X，LIU X，et al. Research progress in treat‐ cer in China：a cost-effectiveness analysis[J]. BMJ Open，
ment of Her-2-positive breast cancer with targeted agents 2022，12（11）：e065299.
[J]. J Chin Oncol，2020，26（1）：1-6. [16] WANG H，ZENG C X，LI X，et al. Cost-utility of afatinib
[ 6 ] CAMERON D，PICCART-GEBHART M J，GELBER R and gefitinib as first-line treatment for EGFR-mutated
D，et al. 11 years’ follow-up of trastuzumab after adjuvant advanced non-small-cell lung cancer[J]. Future Oncol，
chemotherapy in HER2-positive early breast cancer：final 2019，15（2）：181-191.
analysis of the HERceptin Adjuvant （HERA） trial[J]. Lan‐ [17] 高红婷，胡梦雪，贾琳琳，等. 信迪利单抗联合化疗一线
cet，2017，389（10075）：1195-1205. 治疗晚期或复发性非小细胞肺癌的成本-效用分析[J].
[ 7 ] HURVITZ S A，HEGG R，CHUNG W P，et al. Trastu‐ 中国药房，2022，33（15）：1854-1859.
zumab deruxtecan versus trastuzumab emtansine in patients GAO H T，HU M X，JIA L L，et al. Cost-utility analysis of
with HER2-positive metastatic breast cancer：updated sintilimab combined with chemotherapy in first-line treat‐
results from DESTINY-Breast03，a randomised，open- ment of advanced or recurrent non-small cell lung cancer
label，phase 3 trial[J]. Lancet，2023，401（10371）：105-117. [J]. China Pharm，2022，33（15）：1854-1859.
[ 8 ] IM S A，GENNARI A，PARK Y H，et al. Pan-Asian [18] YANG Q，YU X X，ZHANG W. Health variations among
adapted ESMO clinical practice guidelines for the diag- breast-cancer patients from different disease states：evi‐
nosis，staging and treatment of patients with metastatic dence from China[J]. BMC Health Serv Res，2020，20（1）：
breast cancer[J]. ESMO Open，2023，8（3）：101541. 1033.
[ 9 ] GRADISHAR W J，MORAN M S，ABRAHAM J，et al. [19] DOI T，SHITARA K，NAITO Y，et al. Safety，pharmacoki‐
NCCN guidelines insights：breast cancer，version 4.2023 netics，and antitumour activity of trastuzumab deruxtecan
®
[J]. J Natl Compr Canc Netw，2023，21（6）：594-608. （DS-8201），a HER2-targeting antibody-drug conjugate，
[10] YANG J P，HAN J Q，ZHANG Y L，et al. Cost- in patients with advanced breast and gastric or gastro-
effectiveness analysis of trastuzumab deruxtecan versus oesophageal tumours：a phase 1 dose-escalation study[J].
trastuzumab emtansine for HER2-positive breast cancer Lancet Oncol，2017，18（11）：1512-1522.
[J]. Front Pharmacol，2022，13：924126. [20] 李欣 . 从肿瘤药物的慈善赠药谈我国的患者援助项目
[11] ZHU Y W，LIU K，WANG M，et al. Trastuzumab deruxte‐ [J]. 西部学刊，2022（13）：172-176.
can versus trastuzumab emtansine for patients with human LI X. Discussion on patient assistance projects in China
epidermal growth factor receptor 2-positive metastatic from the perspective of charitable donation of tumor drugs
breast cancer：a cost-effectiveness analysis[J]. Breast， [J]. J West，2022（13）：172-176.
2022，66：191-198. [21] OGITANI Y，AIDA T，HAGIHARA K，et al. DS-8201a，a
[12] 刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国 novel HER2-targeting ADC with a novel DNA topoiso-
市场出版社，2020：27-46. merase Ⅰ inhibitor，demonstrates a promising antitumor
LIU G E. China guidelines for pharmacoeconomic evalua‐ efficacy with differentiation from T-DM1[J]. Clin Cancer
tions 2020[M]. Beijing：China Market Press，2020：27-46. Res，2016，22（20）：5097-5108.
[13] 中国临床肿瘤学会 . 中国临床肿瘤学会（CSCO）乳腺癌 （收稿日期：2023-07-29 修回日期：2023-12-25）
诊疗指南 2023[Ｍ]. 北京：人民卫生出版社，2023：87. （编辑：孙 冰）

中国药房 2024年第35卷第2期 China Pharmacy 2024 Vol. 35 No. 2 · 209 ·